arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Scientific Programme

Thursday 07 Nov

Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC)

Chair: Jan B. Vermorken (BE)

13:00

Welcome

13:30

Promising biomarkers for early diagnosis and prognosis prediction in HNS

Phil Sloan (UK)

13:50

Biomarkers to predict radiotherapy toxicity

Mahmut Ozsahin (CH)

14:10

Biomarkers for hypoxia, HPVness and proliferation from imaging perspective

Philippe Lambin (NL)

14:30

Mechanism of cetuximab resistance and how to overcome it

An Wouters (BE)

15:00

Coffee break

15:30

The role of liquid biopsy for monitoring disease evolution

Inge Tinhofer (DE)

15:50

NK cells in immunotherapy: how important are they?

Marco Merlano (IT)

16:10

Biomarkers for immune modulatory treatment in HNSCC

Danny Rischin (AU)

16:30

General discussion

16:45

Proffered paper session

PP02 Integrin avß3 as potential target for imaging angiogenesis in patients with head and neck squamous cell carcinomas using 68Ga-RGD2 PET/CT
Daphne Loobeek (NL)

PP03 Characterization of cetuximab resistance mechanisms in head and neck squamous cell carcinoma cell ines: focus on the contribution of Akt
Ines de Pauw (BE)

PP04 Induction chemotherapy followed by definitive Radiotherapy + Cetuximab versus Chemoradiotherapy in squamous cell carcinoma of head and neck  (SCCHN). The INTERCEPTOR-GONO phase III randomized trial (NCT00999700)
Nerina Denaro ( IT)

17:30

Clinical cases: Panel discussion chaired by Jean-Pascal Machiels

Panel: René Leemans, Volker Budach, Jan Vermorken, Amanda Psyrri, Ethan Argiris

18:30

Welcome reception

Friday 08 Nov

Primary disease (1)

Chair: Volker Budach (DE)

08:45

Novel approaches in surgical management of HNSCC

Piero Nicolai (IT)

09:05

The surgical approach to elderly patients with HNSCC

Andreas Dietz (DE)

09:25

The nonsurgical approach to locoregionally advanced HNSCC

Brian O’Sullivan (CA)

09:45

High-dose three-weekly or low-dose weekly cisplatin during radiation, what to prefer?

Petr Szturz (CH)

10:05

General discussion

10:15

Proffered paper session

PP05 The Effect of Prophylactic Low Level Laser Therapy on Oral Mucositis Following Chemoradiotherapy in Head and Neck Cancers: A Systematic Review
Hassan Baig (UK)

PP06 Causal analyses of retrospective patient data to provide real-world evidence of treatment efficacy: the case of cisplatin in HPV-positive OPSCC
Irene Nauta (NL)

10:45

Coffee break

11:15

Clinical cases: Panel discussion chaired by Volker Budach

Panel: René Leemans, Jean-Pascal Machiels, Brian O’Sullivan, Amanda Psyrri, Ethan Argiris

12:15

Lunch and poster viewing

13:00

MSD Symposium: Integrating the New Treatment Paradigm in 1L R/M HNSCC into Clinical Practice

Programme -> Sponsored symposium

Primary disease (2)

Chair: René Leemans (NL)

14:00

Where and when to use induction chemotherapy?

Jan Vermorken (BE)

14:20

Prognostic role of p16/HPV in non-oropharyngeal head and neck cancer

Amanda Psyrri (GR)

14:40

Is there a role for neoadjuvant targeted and immunotherapies?

Jean-Pascal Machiels (BE)

15:00

Is there a role for adjuvant targeted and immunotherapies?

Kevin Harrington (UK)

15:20

Optimal supportive measures during primary treatment

Paolo Bossi (IT)

15:40

General discussion

16:00

Coffee break

16:30

Proffered paper session

PP07 Papilloma Virus associated Oropharyngeal Cancer following Radical Chemoradiotherapy or Radiotherapy)
Georgina Casswell (AU)

PP08 Activation of immune responses in patients with relapsed-metastatic head and neck cancer: the CONFRONT phase Ib-II trial. (Eudract 2017-000353-39)
Marco Merlano (IT)

PP09 International survey on electronic patient-reported outcomes by the EORTC young Radiation Oncology Group
Alexander Thieme (DE)

17:15

Keynote lecture: Precision Medicine in head and neck cancer: myth or reality

Lillian Siu (CA)

18:00

Adjourn

Saturday 09 Nov

Recurrent and / or metastatic disease

Chair: Brian O’Sullivan (CA)

08:45

Salvage surgery: candidates, safe reconstruction, and results?

René Leemans (NL) and Sat Parmar (UK)

09:15

Re-irradiation for local relapses or second primaries: when and how?

Volker Budach (DE)

09:35

New promising targeted agents in first and second-line settings

Ethan Argiris (GR)

09:55

Update of immune therapies in recurrent/metastatic HNSCC

Danny Rischin (AU)

Special Issue

10:15

Patients with rare head neck cancers: do they need a different approach?

Carla Van Herpen (NL)

10:45

Coffee break

Nasopharynx cancer

Chair: Jean-Pascal Machiels

11:15

New epidemiological aspects

Gemma Gatta (IT)

11:35

New developments in the management of nasopharyngeal carcinoma

Yugan Tao (FR)

12:00

New drugs for recurrent/metastatic nasopharynx cancer

Lillian Siu (CA)

12:20

Discussion

12:30

Closing